|

GI-108 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • GI Innovation, Inc.1

Indications

  • Renal Cell Carcinoma (RCC)1
  • Head and Neck (HNSCC)1
  • Metastatic Solid Tumor1
  • Non-small Cell Lung Cancer (NSCLC)1
  • Pancreatic Cancer1

Other1 trial

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.